First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? - Wikidata - awgldk - TriplyDB

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

http://www.wikidata.org/entity/Q54110124

about

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

http://www.wikidata.org/entity/Q54110124

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@en

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@nl

type

label

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@en

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@nl

prefLabel

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@en

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@nl

P1433

Q54110124-95ACA6DD-B3F1-4461-A88A-760BF533E5B1

P1476

Q54110124-12D2427B-140D-44C1-97CE-2906472AD748

P2093

Q54110124-015FCA46-8D99-417F-A5D2-98A0EB39D06B

P2860

Q54110124-026DB8AB-A8F5-4EA5-9CE1-BB5CC3F4AEC3

Q54110124-04863A29-2485-4C76-B59B-0BEFF42BA2CD

Q54110124-0AD23986-C32E-453E-9B84-7348CEB6AA0E

Q54110124-114D34D4-EF5A-407C-BBF4-943E21C8AA0A

Q54110124-1771E89E-5544-4A65-9503-392DFD96B8EE

Q54110124-1BE419C5-6A59-4FA3-AA08-C03C01136345

Q54110124-206ACC80-6AFA-46A4-BEDC-604E2131BBB6

Q54110124-22C4AD87-5F69-4A64-9779-CCE17A9F1708

Q54110124-2B57BAD4-4ED4-40AF-AE7E-91A263A304E0

Q54110124-313361E7-C716-4E2E-8189-663A70A6D37F

P304

Q54110124-DC88FC72-3E4B-4C51-8B4A-94A3000E4662

P31

Q54110124-F80E817E-B6A7-4A8C-BD58-452B592687A6

P356

Q54110124-067E513E-178B-4107-9A90-EEA1C8674663

P478

Q54110124-E13C9019-EB91-434F-BE8A-6E28675DEAB5

P50

Q54110124-CDB779E3-D1C7-4EB6-AC8F-D5666114291C

P577

Q54110124-95E982D0-FADE-4D7D-BE29-BA2ADE257750

P698

Q54110124-79208C93-6659-4292-BEF6-930B6C84464F

P932

Q54110124-FF2A52E5-BE03-484D-BF08-81CDECCF2B48

P356

FONC.2018.00094

P1433

Frontiers in Oncology

P1476

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

@en

P2093

Hatim Husain

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P304

94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00094

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29755953

http://www.w3.org/2001/XMLSchema#string

P932

5932412

http://www.w3.org/2001/XMLSchema#string